Ads
related to: pompe disease sanofi treatment mayo clinic
Search results
Results From The WOW.Com Content Network
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder [1] which damages muscle and nerve cells throughout the body.
These trials enrolled 124 participants with late-onset Pompe disease and 22 participants with infantile-onset Pompe disease. [9] The participants were from 22 countries around the world, including the United States. [9] Avalglucosidase alfa was evaluated in four trials of 146 participants with Pompe disease. [9]
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD). [6] Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha ...
For premium support please call: 800-290-4726 more ways to reach us
The FDA has placed a clinical hold on Astellas Pharma Inc's (OTC: ALPMY) FORTIS Phase 1/2 trial following a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial ...
Cipaglucosidase alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type II (Pompe disease). [4] [5] Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α-glucosidase ...
Ads
related to: pompe disease sanofi treatment mayo clinic